 Sarepta Therapeutics Inc NASDAQ: SRPT shared new analyses and functional data from its SRP-9001 development program and the details of Study SRP-9001-301 EMBARK Phase 3 trial of SRP-9001 for Duchenne muscular dystrophy. SRP-9001, being developed in partnership with Roche Holdings AG OTC: RHHBY, is an investigational gene transfer therapy intended to deliver its micro-dystrophin-encoding gene to muscle tissue. 